

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-13 (canceled).

14 (currently amended). A pharmaceutical composition comprising at least one CD23-binding peptide, wherein said peptide is selected from the group consisting of consisting of the amino acid sequence:

Phe-His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:1);  
~~Phe-His-Glu-Phe-Trp-Pro-Thr (SEQ ID NO:2);~~  
~~Phe-His-Ser-Gln-Trp-Pro-Asn (SEQ ID NO:3);~~  
~~Phe-His-Glu-Asn-Trp-Pro (SEQ ID NO:4);~~  
~~Phe-His-Glu-Asn-Trp-Pro-Thr (SEQ ID NO:5);~~  
~~Phe-His-Glu-Gln-Trp-Pro-Ser (SEQ ID NO:6);~~  
~~His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:7);~~  
~~His-Lys-Asn-Trp-Pro-Ser (SEQ ID NO:8);~~  
~~His-Glu-Asn-Trp-Pro-Ser-Phe (SEQ ID NO:9);~~  
~~Phe-His-Lys-Pro-Trp-Arg-Ala (SEQ ID NO:10);~~  
~~His-Glu-Asn-Trp-Lys-Ser (SEQ ID NO:31);~~  
~~His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:32);~~  
~~His-Glu-Asn-Trp-Gly-Ser (SEQ ID NO:34);~~  
~~His-Glu-Asn-Trp-Glu-Ser (SEQ ID NO:35);~~  
~~Phe-His-Glu-Ala-Trp-Pro-Ser (SEQ ID NO:40);~~

~~Phe-His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:43);~~  
~~His-Glu-Asn-Ala-Pro-Ser (SEQ ID NO:53);~~  
~~His-Glu-Asn-Trp-Ser (SEQ ID NO:54);~~  
~~G[allyl]-N-W-G[allyl] (SEQ ID NO:55);~~  
~~NH<sub>2</sub>-G[allyl]-N-W-G[allyl] (SEQ ID NO:56);~~  
~~Ac-wn-CO<sub>2</sub>H (SEQ ID NO:57);~~  
~~Ac-NW-CO<sub>2</sub>H (SEQ ID NO:58);~~  
~~Ac-n-w-CO<sub>2</sub>H (SEQ ID NO:59);~~  
~~Ac-N-W-BetaA-CO<sub>2</sub>H (SEQ ID NO:60); and~~  
~~H-E-N-W-P-CONH<sub>2</sub> (SEQ ID NO:61);~~

and a pharmaceutically acceptable carrier.

15-39 (canceled).

40 (previously presented). The peptide according to Claim 59 having a specific binding to CD23 of at least about  $10^{-6}$  M.

41-57(canceled).

58 (previously presented). The composition according to claim 14 wherein said peptide comprises at least one amino acid which is D-isomer.

59 (currently amended). A CD23-binding peptide, wherein said peptide comprises the amino acid sequence of any one of SEQ ID NOs: 2 to 10, 31, 32, 34, 35, 40, 43 and 53-64 consists of:

Phe-His-Glu-Phe-Trp-Pro-Thr (SEQ ID NO:2);  
Phe-His-Ser-Gln-Trp-Pro-Asn (SEQ ID NO:3);  
Phe-His-Glu-Asn-Trp-Pro (SEQ ID NO:4);  
Phe-His-Glu-Asn-Trp-Pro-Thr (SEQ ID NO:5);  
Phe-His-Glu-Gln-Trp-Pro-Ser (SEQ ID NO:6);  
His-Glu-Asn-Trp-Pro-Ser (SEQ ID NO:7);  
His-Lys-Asn-Trp-Pro-Ser (SEQ ID NO:8);  
His-Glu-Asn-Trp-Pro-Ser-Phe (SEQ ID NO:9);  
Phe-His-Lys-Pro-Trp-Arg-Ala (SEQ ID NO:10);  
His-Glu-Asn-Trp-Lys-Ser (SEQ ID NO:31);  
His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:32);  
His-Glu-Asn-Trp-Gly-Ser (SEQ ID NO:34);  
His-Glu-Asn-Trp-Glu-Ser (SEQ ID NO:35);  
Phe-His-Glu-Ala-Trp-Pro-Ser (SEQ ID NO:40);  
Phe-His-Glu-Asn-Trp-Xaa-Ser (SEQ ID NO:43);  
His-Glu-Asn-Ala-Pro-Ser (SEQ ID NO:53);  
His-Glu-Asn-Trp-Ser (SEQ ID NO:54);  
G[allyl-] N W G[allyl-] (SEQ ID NO:55);  
NH<sub>2</sub> Grallyl-] N W G[allyl-] (SEQ ID NO:56);  
Ac wn CO<sub>2</sub>H (SEQ ID NO:57);

Ac NW CO<sub>2</sub>H (SEQ ID NO:58);  
Ac n w CO<sub>2</sub>H (SEQ IDNO:59);  
Ac N W BetaA CO<sub>2</sub>H (SEQ ID NO:60); or  
H E N W P CONH<sub>2</sub> (SEQ ID NO:61).

60 (previously presented). The peptide according to claim 59 comprising at least one amino acid which is a D-isomer, an acylated N-terminus, and acetylated N-terminus or amidated C-terminus.

61 (currently amended). The composition according to Claim 14 wherein said ~~peptide comprises an~~ the N-terminus and wherein said N-terminus of said peptide is acylated.

62 (currently amended). The composition according to Claim 61 wherein said the N-terminus of said peptide is acetylated.

63 (currently amended). The composition according to Claim 14 wherein said ~~peptide comprises a C-terminus and wherein said~~ the C-terminus of said peptide is amidated.

64 (previously presented). A peptide of claim 59 wherein said peptide is labeled with a detectable marker.